Sayer Ji
Founder of GreenMedInfo.com

Subscribe to our informative Newsletter & get two FREE E-Books

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Depression: 21st Century Solutions + The Dark Side of Wheat

Abstract Title:

Curcumin diminishes human osteoclastogenesis by inhibition of the signalosome-associated I kappaB kinase.

Abstract Source:

J Cancer Res Clin Oncol. 2009 Feb;135(2):173-9. Epub 2008 Sep 3. PMID: 18766375

Abstract Author(s):

Ivana von Metzler, Holger Krebbel, Ulrike Kuckelkorn, Ulrike Heider, Christian Jakob, Martin Kaiser, Claudia Fleissner, Evangelos Terpos, Orhan Sezer

Article Affiliation:

Department of Hematology and Oncology, Charitéplatz 1, Charité, Universitätsmedizin Berlin, 10117, Berlin, Germany.

Abstract:

PURPOSE: Curcumin is a natural polyphenolic derogate extracted from spice turmeric, exhibiting anti-inflammatory and chemopreventive activities. It was described to interact with the signalosome-associated kinases and the proteasome-ubiquitin system, which both are involved in the osteoclastogenesis. Thus, we hypothesized that curcumin could diminish osteoclast differentiation and function.

METHODS: For the experiments considering osteoclast differentiation and resorptional activities, preosteoclasts were cultured for 4 weeks and treated with curcumin at subapoptotic dosages. Derived mature osteoclasts were identified as large, multinucleated cells with expression of tartrate-resistant acid phosphatase activity. Formation of resorption lacunae, a hallmark of osteoclast activity, was quantified using dentine pits and light microscopy. The signaling pathways were examined by ELISA-based methods and by immunoblotting.

RESULTS: Both 1 and 10 microM curcumin abrogated osteoclast differentiation (by 56 and 81%) and function (by 56 and 99%) (P<0.05) dose-dependently. The effects were accompanied by the inhibition of I kappaB phosphorylation and NF-kappaB activation. In contrast, subtoxic doses did not have any significant effects on proteasome inhibition.

CONCLUSION: This manuscript is the first report that describes the effects of curcumin toward human osteoclastogenesis, and builds the framework for clinical trials of curcumin in the treatment of cancer-induced lytic bone disease.

Study Type : In Vitro Study

Print Options


Key Research Topics

Sayer Ji
Founder of GreenMedInfo.com

Subscribe to our informative Newsletter & get two FREE E-Books

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Depression: 21st Century Solutions + The Dark Side of Wheat

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2019 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.